References
- Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFV)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983–2990.
- Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
- Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994;84:4310–4315.
- Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 2006;130:374–377.
- Johrens K, Happerfield LC, Brown JP, et al. A novel CD11c monoclonal antibody effective in formalin-fixed tissue for the diagnosis of hairy cell leukemia. Pathobiology 2008;75:252–256.
- Went PT, Zimpfer A, Pehrs AC, et al. High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. Am J Surg Pathol 2005;29:474–478.
- Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–1896.